TY - JOUR T1 - Carboplatin plus Weekly Paclitaxel Treatment in Non-small Cell Lung Cancer Patients with Interstitial Lung Disease JF - Anticancer Research JO - Anticancer Res SP - 4357 LP - 4361 VL - 30 IS - 10 AU - T. SHUKUYA AU - T. ISHIWATA AU - M. HARA AU - K. MURAKI AU - R. SHIBAYAMA AU - R. KOYAMA AU - K. TAKAHASHI Y1 - 2010/10/01 UR - http://ar.iiarjournals.org/content/30/10/4357.abstract N2 - Background: Since advanced non-small cell lung cancer (NSCLC) patients with the interstitial lung disease (ILD) have been excluded from clinical trials, it is uncertain whether chemotherapy really provides a benefit to these patients. Patients and Methods: Fifteen advanced NSCLC patients with ILD that was detected on the chest X-rays were enrolled in this study. Carboplatin plus paclitaxel was administered by two methods (method A or method B). Method A: Carboplatin (AUC 6, day 1) and paclitaxel (70 mg/m2, days 1, 8, 15) were administered every four weeks. Method B: Carboplatin (AUC 2, day 1, 8, 15) and paclitaxel (60 mg/m2, days 1, 8, 15) were administered every four weeks. Results: The response rate and the disease control rate were 33% and 53%. The median progression-free survival and the median overall survival time were 2.5 months and 7.0 months, respectively. The hematological toxicities were tolerable, but a grade 3 or higher pneumonitis was observed in 4 patients (27%). Conclusion: Carboplatin plus weekly paclitaxel must be administered carefully to advanced NSCLC patients with ILD that is detected on chest X-rays after a sufficient evaluation of the risks and the benefits. ER -